Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitor BMS-986158 in Pediatric Cancer
Status:
Recruiting
Trial end date:
2024-07-10
Target enrollment:
Participant gender:
Summary
This research study is studying an investigational drug called BMS-986158 as a possible
treatment for pediatric solid tumors, lymphoma, or brain tumors.